Nuzenio

Karyopharm

Karyopharm news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 17 latest news signals 10 publisher sources 100/100 entity strength

Latest news

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - KaryopharmKaryopharm · Mon, 03 Aug 2026 20:05:15 GMTKaryopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Sat, 01 Aug 2026 06:33:05 GMTKaryopharm To Stick With Blood Cancers As Xpovio Flops In Endometrial Cancer - insights.citeline.cominsights.citeline.com · Fri, 31 Jul 2026 20:31:57 GMTBaird Downgrades Karyopharm Therapeutics(KPTI.US) to Hold Rating - MoomooMoomoo · Fri, 31 Jul 2026 16:12:53 GMTJefferies Initiates Karyopharm Therapeutics(KPTI.US) With Buy Rating, Announces Target Price $11 - MoomooMoomoo · Fri, 31 Jul 2026 15:31:00 GMTXpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis - Fierce PharmaFierce Pharma · Fri, 31 Jul 2026 14:00:00 GMTKaryopharm Therapeutics reports Phase 3 XPORT-EC-042 misses PFS; plans myelofibrosis sNDA - TradingViewTradingView · Fri, 31 Jul 2026 12:33:01 GMTKaryopharm plans selinexor-ruxolitinib combination filing for myelofibrosis accelerated approval - AllSciAllSci · Fri, 31 Jul 2026 12:29:21 GMT

Timeline

Mon, 03 Aug 2026 20:05:15 GMTKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Sat, 01 Aug 2026 06:33:05 GMTKaryopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial Vanguard
Fri, 31 Jul 2026 20:31:57 GMTKaryopharm To Stick With Blood Cancers As Xpovio Flops In Endometrial Cancer - insights.citeline.com
Fri, 31 Jul 2026 16:12:53 GMTBaird Downgrades Karyopharm Therapeutics(KPTI.US) to Hold Rating - Moomoo
Fri, 31 Jul 2026 15:31:00 GMTJefferies Initiates Karyopharm Therapeutics(KPTI.US) With Buy Rating, Announces Target Price $11 - Moomoo
Fri, 31 Jul 2026 14:00:00 GMTXpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis - Fierce Pharma

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.PoliticsPolitics stories explain decisions, institutions, parties, leaders, laws, budgets, elections, courts, and public accountability.

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Karyopharm.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

10 distinct publisher/source names are currently connected to this entity page.